Evidence map›Paper›PMID 36296424›Full record

ArticleMolecules (Basel, Switzerland)2022

Assembly of Biologically Functional Structures by Nucleic Acid Templating: Implementation of a Strategy to Overcome Inhibition by Template Excess.

Matthew M Lawler, James T Kurnick, Leah Fagundes St Pierre, Estelle E Newton, Lenora B Rose, Ian S Dunn

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew M LawlerTriBiotica LLC, 100 Cummings Center, Suite 424-J, Beverly, MA 01915, USA.
James T KurnickDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Leah Fagundes St PierreTriBiotica LLC, 100 Cummings Center, Suite 424-J, Beverly, MA 01915, USA.
Estelle E NewtonTriBiotica LLC, 100 Cummings Center, Suite 424-J, Beverly, MA 01915, USA.
Lenora B RoseTriBiotica LLC, 100 Cummings Center, Suite 424-J, Beverly, MA 01915, USA.
Ian S DunnTriBiotica LLC, 100 Cummings Center, Suite 424-J, Beverly, MA 01915, USA.
Massachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delivery of therapeutic molecules to pathogenic cells is often hampered by unintended toxicity to normal cells. In principle, this problem can be circumvented if the therapeutic effector molecule is split into two inactive components, and only assembled on or within the target cell itself. Such an in situ process can be realized by exploiting target-specific molecules as templates to direct proximity-enhanced assembly. Modified nucleic acids carrying inert precursor fragments can be designed to co-hybridize on a target-specific template nucleic acid, such that the enforced proximity accelerates assembly of a functional molecule for antibody recognition. We demonstrate the in vitro feasibility of this adaptation of nucleic acid-templated synthesis (NATS) using oligonucleotides bearing modified peptides ("haplomers"), for templated assembly of a mimotope recognized by the therapeutic antibody trastuzumab. Enforced proximity promotes mimotope assembly via traceless native chemical ligation. Nevertheless, titration of participating haplomers through template excess is a potential limitation of trimolecular NATS. In order to overcome this problem, we devised a strategy where haplomer hybridization can only occur in the presence of target, without being subject to titration effects. This generalizable NATS modification may find future applications in enabling directed targeting of pathological cells.

Indexed as

Nucleic AcidsDNAOligonucleotidesPeptidesTrastuzumabDNANucleic AcidsOligonucleotidesPeptidesTrastuzumabantibody epitopechemical modificationmolecular proximitynucleic acidstemplated assemblytemplate titration

Identifiers

PMID36296424
PMCPMC9610079
OpenAlexW4304806291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.